替米沙坦对糖尿病合并阵发性心房颤动患者的影响

Effects of telmisartan on diabetic patients with paroxysmal atrial fibrillation

目的探讨替米沙坦对2型糖尿病并阵发性心房颤动(简称房颤)患者的影响。方法选取93例糖尿病合并阵发性房颤患者,随机分成替米沙坦治疗组与对照组。治疗组在由原降糖药物基础上加用口服替米沙坦80mg/d,对照组仅继续使用原降糖药物。观察6个月,记录治疗前后房颤发作情况,检测治疗前和治疗6个月后的左房内径、血浆血管假性血友病因子(vWF)和一氧化氮(NO)浓度。结果治疗组维持窦性心律的情况明显优于对照组(81.3%vs 66.7%,P<0.05)。和对照组比较,治疗组6个月后内皮功能明显改善(P<0.05)。结论替米沙坦可能有利于糖尿病并阵发性房颤患者维持窦性心律及改善内皮功能。

Objective To investigate the effect of telmisartan on patients with type 2 diabetes and paroxysmal atrial fibrillation （AF）. Methods Ninty-three patients with well-controlled type 2 diabetes who also suffered paroxysmal AF were randomized to treatment group （ 80 mg of telmisartan plus hypoglycemic agent） or to control group （ hypoglycemic agent only） and were followed up for 6 monthes. A 24-hour ECG were evaluated monthly. The patients were asked to report any episode of symptomatic AF and to obtain its ECG recording as early as possible. Nitric oxide （NO） and von Willebrand factor （vWF） were quantified before and after 6month therapy. Results The situation of maintaining sinus rhythm was reported in 81.3% of the patients treated with telmisartan and in 66.7% of those treated without telmisartan, with a signifi- cant difference between treatments （ P 〈 0.05 ）. Improvement of endothelial function of patients in telmisartan treatment group was better than that in the control group （ P 〈 0. 05 ）. Conclusion Telmisartan can improve the situation of maintaining sinus rhythm and endothelial function in diabetic patients with paroxysmal atrial fibrillation.